Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:BCLI
- CUSIP: N/A
- Web: www.brainstorm-cell.com
Capitalization:- Market Cap: $92.55 million
- Outstanding Shares: 18,735,000
Average Prices:- 50 Day Moving Avg: $4.29
- 200 Day Moving Avg: $3.85
- 52 Week Range: $2.06 - $5.18
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.76
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.44 per share
- Price / Book: 11.23
Profitability:- EBIDTA: ($4,960,000.00)
- Return on Equity: -49.12%
- Return on Assets: -44.58%
Debt:- Current Ratio: 11.18%
- Quick Ratio: 11.18%
Misc:- Average Volume: 101,530 shs.
- Beta: 2.26
- Short Ratio: 9.81
Frequently Asked Questions for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
What is Brainstorm Cell Therapeutics' stock symbol?
Brainstorm Cell Therapeutics trades on the NASDAQ under the ticker symbol "BCLI."
How were Brainstorm Cell Therapeutics' earnings last quarter?
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) released its quarterly earnings data on Monday, May, 15th. The company reported ($0.10) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.30) by $0.20. View Brainstorm Cell Therapeutics' Earnings History.
When will Brainstorm Cell Therapeutics make its next earnings announcement?
Where is Brainstorm Cell Therapeutics' stock going? Where will Brainstorm Cell Therapeutics' stock price be in 2017?
1 brokerages have issued 1 year price objectives for Brainstorm Cell Therapeutics' stock. Their forecasts range from $8.00 to $8.00. On average, they expect Brainstorm Cell Therapeutics' share price to reach $8.00 in the next twelve months. View Analyst Ratings for Brainstorm Cell Therapeutics.
Who are some of Brainstorm Cell Therapeutics' key competitors?
Some companies that are related to Brainstorm Cell Therapeutics include Compugen (CGEN), Novelion Therapeutics (NVLN), Merrimack Pharmaceuticals (MACK), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), Chromadex Corp (CDXC), OncoMed Pharmaceuticals (OMED), Matinas BioPharma Holdings (MTNB), Pluristem Therapeutics (PSTI), Oramed Pharmaceuticals (ORMP), CTI BioPharma Corp. (CTIC), Vernalis plc (VER), BioLineRx (BLRX), ArQule (ARQL), CytRx Corporation (CYTR), GTx (GTXI) and Tissue Regenix Group PLC (TRX).
Who are Brainstorm Cell Therapeutics' key executives?
Brainstorm Cell Therapeutics' management team includes the folowing people:
- Irit Arbel, Chairman of the Board
- Chaim Lebovits, Chief Executive Officer
- Yoram Bibring CPA, Chief Financial Officer, Treasurer
- Ralph Kern, Chief Operating Officer and Chief Medical Officer
- Uri Yablonka, Executive Vice President, Chief Business Officer, Director
- Alla Patlis, Controller
- June S. Almenoff M.D. Ph.D., Independent Director
- Arturo Araya, Independent Director
- Mordechai Friedman, Independent Director
- Alon Pinkas, Independent Director
How do I buy Brainstorm Cell Therapeutics stock?
Shares of Brainstorm Cell Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Brainstorm Cell Therapeutics' stock price today?
One share of Brainstorm Cell Therapeutics stock can currently be purchased for approximately $4.94.
MarketBeat Community Rating for Brainstorm Cell Therapeutics (NASDAQ BCLI)MarketBeat's community ratings are surveys of what our community members think about Brainstorm Cell Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Brainstorm Cell Therapeutics (NASDAQ:BCLI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Buy Rating |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $8.00 (61.94% upside) |
Analysts' Ratings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/22/2017 | Maxim Group | Set Price Target | Buy | $8.00 | Low |  |
(Data available from 7/24/2015 forward)
Earnings History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)Earnings History by Quarter for Brainstorm Cell Therapeutics (NASDAQ BCLI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/9/2017 | | ($0.15) | | | | | N/A | |
| 5/15/2017 | Q1 2017 | ($0.30) | ($0.10) | | | View | N/A | |
| 3/30/2017 | Q4 2016 | ($0.07) | ($0.03) | | | View | N/A | |
| 11/14/2016 | Q3 2016 | ($0.11) | ($0.09) | | | View | N/A | |
| 8/11/2016 | Q2 | ($0.18) | ($0.05) | | | View | N/A | |
| 5/10/2016 | Q116 | ($0.25) | ($0.10) | | | View | N/A | |
| 3/10/2016 | Q415 | ($0.15) | ($0.07) | | | View | N/A | |
| 11/17/2015 | Q3 | ($0.14) | ($0.14) | | | View | N/A | |
| 8/13/2015 | Q215 | ($0.13) | ($0.12) | | | View | Listen | |
| 5/14/2015 | Q115 | ($0.14) | ($0.12) | | | View | Listen | |
| 3/26/2015 | Q414 | ($0.18) | ($0.18) | | | View | N/A | |
| 11/13/2014 | | ($0.12) | ($0.16) | | | View | N/A | |
| 11/13/2014 | Q3 14 | ($0.12) | ($0.16) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Brainstorm Cell Therapeutics (NASDAQ:BCLI)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
| Q3 2017 | 1 | ($0.10) | ($0.10) | ($0.10) |
(Data provided by Zacks Investment Research)
Dividend History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Brainstorm Cell Therapeutics (NASDAQ:BCLI)Insider Ownership Percentage: 23.70%
Institutional Ownership Percentage: 7.98%
Insider Trades by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/16/2015 | Robert G L Shorr | Director | Sell | 10,800 | $2.71 | $29,268.00 | |
| 12/15/2015 | Malcolm S. Taub | Director | Sell | 41,742 | $2.60 | $108,529.20 | |
| 12/11/2015 | Malcolm S. Taub | Director | Sell | 13,480 | $2.73 | $36,800.40 | |
| 10/1/2015 | International Holdings Ltd Acc | Major Shareholder | Buy | 2,000 | $2.58 | $5,160.00 | |
| 9/30/2015 | International Holdings Ltd Acc | Major Shareholder | Buy | 9,200 | $2.34 | $21,528.00 | |
| 8/20/2015 | Yoram Bibring | CFO | Buy | 8,500 | $3.04 | $25,840.00 | |
| 8/17/2015 | Yoram Bibring | CFO | Buy | 41,500 | $2.92 | $121,180.00 | |
| 10/10/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 8,600 | $4.06 | $34,916.00 | |
| 10/1/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 6,700 | $4.14 | $27,738.00 | |
| 9/22/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 11,000 | $4.17 | $45,870.00 | |
| 9/15/2014 | Anthony S Fiorino | CEO | Buy | 18,000 | $0.28 | $5,040.00 | |
| 6/16/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 130,000 | $0.29 | $37,700.00 | |
| 6/13/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 150,000 | $0.35 | $52,500.00 | |
| 4/28/2014 | International Holdings Ltd Acc | Major Shareholder | Buy | 939,600 | $0.30 | $281,880.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
Latest Headlines for Brainstorm Cell Therapeutics (NASDAQ:BCLI)
| Source: |
|
Brainstorm Cell Therapeutics (BCLI) Chart for Monday, July, 24, 2017
